Krystal Biotech Inc. is a commercial-stage biotechnology company that discovers, develops, manufactures, and commercializes genetic medicines for diseases with high unmet need. Its proprietary platform uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver therapeutic transgenes to target cells. The company's lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved for the treatment of dystrophic epidermolysis bullosa, a rare genetic skin disorder. Krystal Biotech manufactures VYJUVEK at its own facilities and sells it in the United States, the European Union, and Japan. The company operates as a single pharmaceutical segment, generating revenue primarily from product sales of VYJUVEK, and also pursues earlier-stage programs in aesthetic and respiratory indications based on its HSV-1 vector platform.

Interest Coverage

Beneish M-Score

Financial Strength